Diopsys® ERG tests use electroretinography (ERG) technology to help eye care specialists gain objective, functional information about the performance of the inner retinal cells of the eye, especially in the macula. Diopsys offers two ERG modules – Contrast Sensitivity and Concentric Stimulus Fields.
- Both objective and functional test results, no verbal response or “button pushing” required.
- Color-coded reports for rapid, intuitive report interpretation.
- Enhanced treatment tracking and patient management with quantitative data.
- All Diopsys ERG tests conform to the standards of the International Society for Clinical Electrophysiology of Vision (ISCEV)
Concentric Stimulus Fields
Information gathered is intended to be used to aid in the diagnosis and care of diseases that affect the retina in specific topographic patterns, i.e., Age Related Macular Degeneration (AMD), Diabetes Macular Edema (CME) and Toxic Maculopathies (e.g. Plaquenil Maculopathy). These types of diseases usually have an expected pattern of macular deterioration, affecting the central or paracentral area of the macula.
The Diopsys ERG Concentric Stimulus Fields test utilizes two different degrees of stimulus presented as concentric circles with contrast reversing patterns.
Designed to provide data to aid in the diagnosis and care of diseases that affect the retina in a diffuse pattern like Chronic Open Angle Glaucoma (COAG) and Diabetic Retinopathy (DR). Since there is typically no specific topographic pattern of damage, the information collected using this protocol may help in detecting the depth of the macular dysfunction.
The Diopsys ERG Contrast Sensitivity test utilizes a full screen stimulus with two different contrast levels to give an objective, functional response of the vision system at the retina.
The Diopsys ERG tests are designed to provide data to the doctor to help detect cellular dysfunction that can precede evident structural defects, thereby contributing to earlier detection for more specific and timely management of diseases that impair macula and ganglion cells.
*Although the previously mentioned diseases usually have an expected clinical presentation, they may develop differently. The eye care professional must individualize the usage of the Diopsys ERG tests depending on his/her assessment of the clinical presentation of the disease(s), patient history and risk factors, and changes to the patients’ condition that can result in subclinical manifestations that contribute to vision loss.